• 1
    McHutchison JG, Manns M, Patel K, Poynard T, Lindsey KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10611069.
  • 2
    Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346355.
  • 3
    Whitworth JE, Vanderpoel DR, Miller B. A descriptive assessment of the current treatment patterns for hepatitis C in a health benefits company population. Gastroenterology 2005; 128( Suppl 2): A724A725.
  • 4
    Del Rio RA, Post AB, Singer ME. Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy. HEPATOLOGY 2006; 44: 15981606.
  • 5
    Richardson WS, Detsky AS. Users' guides to the medical literature. VII. How to use a clinical decision analysis. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1995; 273: 12921295.
  • 6
    Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003; 98: 24912499.
  • 7
    Afdhal NH, Dieterich DT, Pockros PJ, Schiff ER, Shiffman ML, Sulkowski MS, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology 2004; 126: 13021311.
  • 8
    Shiffman ML, Price A, Hubbard S, Wilson M, Salvatori J, Sterling RK, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon alfa-2b, high weight based dose ribavirin and epoetin alfa enhances sustained virologic response [Abstract]. HEPATOLOGY 2005; 42( Suppl 1): 217A.
  • 9
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 10
    Stravitz RT, Chung H, Sterling RK, Luketic VA, Sanyal AJ, Price AS, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005; 100: 14151419.
    Direct Link:
  • 11
    Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006; 130: 231264.
  • 12
    Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130: 225230.
  • 13
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438450.
  • 14
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451459.
  • 15
    Castells L, Vargas V, Allende H, Bilbao I, Luis Lazaro J, Margarit C, et al. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 5359.
  • 16
    Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642650.
  • 17
    Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepato-Gastroenterology 1995; 42: 907912.
  • 18
    Lawitz EJ, Hepburn MJ, Casey TJ. A pilot study of interleukin-11 in subjects with chronic hepatitis C and advanced liver disease nonresponsive to antiviral therapy. Am J Gastroenterol 2004; 99: 23592364.
    Direct Link:
  • 19
    McHutchison JG, Afdhal N, Shiffman ML, et al. Efficacy and safety of eltrombopag, an oral platelet growth factor, in sujects with HCV associated thrombocytopenia: preliminary results from a phase II multicenter, randomised, placebo controlled, double-blind, dose-ranging study. Gastroenterology 2006; 130( Suppl 2): A762.
  • 20
    Dev A, Patel K, Muir AJ, McHutchison JG. Erythropoietin for ribavirin induced anemia in hepatitis C: more answers but many more questions. Am J Gastroenterol 2003; 98: 23442347.